Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO-TTR

ConclusionSignificant improvement in Norfolk QOL-DN and SF-36v2 scores, which include several domains related to patient well-being and activities of daily living, suggest that inotersen improves the QOL of patients with hATTR-PN with CM, the hATTR population with the greatest disease burden.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research